US Patent 10,022,379: Linagliptin-Metformin Patent Scope, Expiration, Litigation and Generic Entry Risk
US Patent 10,022,379 protects specific oral tablet regimens combining linagliptin, metformin hydrochloride and a basic amino acid stabilizer, principally L-arginine. The patent is formulation- and dosage-specific rather than a broad patent on linagliptin or metformin. Its strongest commercial relevance is to 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1,000 mg linagliptin-metformin tablets corresponding to Jentadueto products.
The patent was issued on July 17, 2018, to Boehringer Ingelheim International GmbH. Its claims cover methods of treating type 2 diabetes and achieving glycemic control by administering coated or monolayer tablets containing defined percentages of linagliptin, metformin hydrochloride and a stabilizing basic amino acid. The patent is listed in connection with Jentadueto in FDA patent records. Its ordinary patent-term endpoint is expected to fall in the late 2020s, subject to the patent’s recorded terminal disclaimer, patent-term adjustment and any applicable regulatory exclusivity. [1-4]
What drug and product does US Patent 10,022,379 cover?
The long chemical name in the claims identifies linagliptin, the DPP-4 inhibitor marketed by Boehringer Ingelheim under the Tradjenta brand. The claimed combination product is linagliptin plus metformin hydrochloride, marketed in the United States as Jentadueto and Jentadueto XR.
| Claim element |
Patent requirement |
| DPP-4 inhibitor |
Linagliptin |
| Linagliptin strength |
2.5 mg or 5 mg |
| Second active ingredient |
Metformin hydrochloride |
| Stabilizer |
Basic amino acid with an intramolecular amino group and alkaline characteristics |
| Named stabilizers |
L-arginine, L-lysine or L-histidine |
| Dosage form |
Tablet |
| Coating |
Film-coat in claims 1 and 20 |
| Linagliptin percentage |
0.1%-0.5% of total coated tablet mass |
| Metformin percentage |
47%-85% of total coated tablet mass |
| Basic amino acid percentage |
0.07%-2.2% of total coated tablet mass |
| Treatment indication |
Type 2 diabetes mellitus or glycemic control |
The patent does not claim every linagliptin-metformin product. A product must satisfy the claimed active-ingredient strengths, excipient and stabilizer requirements, tablet structure and weight-percentage limitations to present a direct literal infringement risk.
What are the independent claims in US Patent 10,022,379?
Claims 1, 12 and 20 are the principal independent claims.
Claim 1: coated tablet method
Claim 1 requires oral administration of a tablet containing:
- 2.5 mg or 5 mg linagliptin;
- metformin hydrochloride;
- pharmaceutical excipients;
- a basic amino acid in an amount sufficient to suppress linagliptin degradation; and
- a film coat.
The tablet must also contain:
- 0.1%-0.5% linagliptin;
- 47%-85% metformin hydrochloride; and
- 0.07%-2.2% basic amino acid,
with each percentage calculated against the total mass of the coated tablet.
This is a narrow combination claim. It requires both composition limitations and administration of the composition to a patient with type 2 diabetes.
Claim 12: monolayer tablet method
Claim 12 is narrower in tablet architecture. It requires a solid pharmaceutical composition that is a mono-layer tablet containing:
- 2.5 mg linagliptin;
- metformin hydrochloride;
- L-arginine;
- one or more fillers; and
- one or more binders.
The claim further requires:
- linagliptin at approximately 0.2%-0.4% by weight of the total tablet core; and
- a linagliptin-to-L-arginine weight ratio of approximately 1:10 to 10:1.
Claim 12 does not expressly require the film-coat limitation appearing in claim 1. Its focus is the tablet core and the mono-layer structure.
Claim 20: glycemic-control method
Claim 20 substantially tracks claim 1 but changes the therapeutic wording from treatment of type 2 diabetes to achieving glycemic control in a type 2 diabetes patient. It retains the principal formulation and percentage limitations.
How do the dependent claims narrow the patent scope?
The dependent claims identify commercially important dosage combinations and stabilizer choices.
| Dependent claims |
Limitation |
| Claims 2 and 8 |
Basic amino acid includes L-arginine, L-lysine or L-histidine; claim 8 specifically requires L-arginine at about 1-25 mg |
| Claims 3 and 4 |
Linagliptin strength is 5 mg or 2.5 mg |
| Claims 5-7 |
Metformin range is about 100-1,500 mg, with specified strengths including 500, 850 and 1,000 mg |
| Claims 9-11 |
2.5 mg linagliptin combined with 500, 850 or 1,000 mg metformin |
| Claims 13-19 |
Claim 12 combinations using 100-1,500 mg metformin and 500, 850 or 1,000 mg strengths |
Claims 9-11 and 17-19 are the most commercially relevant claims for immediate-release Jentadueto dosage strengths. They cover the principal 2.5 mg linagliptin presentations with 500 mg, 850 mg and 1,000 mg metformin.
What patent protects the Jentadueto linagliptin-metformin combination?
US Patent 10,022,379 is one component of a broader Jentadueto patent estate. The estate includes patents directed to:
- linagliptin as a chemical entity;
- pharmaceutical compositions containing linagliptin;
- linagliptin-metformin combinations;
- stabilized formulations using basic amino acids;
- immediate-release and extended-release dosage forms;
- therapeutic methods for diabetes; and
- manufacturing and solid-form technology.
The relevant distinction is between product-level protection and formulation-level protection.
| Patent category |
Commercial effect |
| Linagliptin compound patent |
Protects the active ingredient across formulations and indications |
| Combination patent |
Protects linagliptin plus metformin products |
| Formulation patent |
Protects defined excipients, stabilizers, tablet structures or release profiles |
| Method-of-use patent |
Protects administration for a defined patient population or therapeutic purpose |
| Manufacturing patent |
Can complicate non-infringing production or supply arrangements |
US 10,022,379 is primarily a formulation and method-of-use patent. It does not independently prevent all manufacture or sale of linagliptin because the claims require the specified metformin-containing tablet and therapeutic administration.
When does US Patent 10,022,379 expire?
The patent issued from a continuation-type prosecution history associated with Boehringer Ingelheim’s linagliptin-metformin development program. Its effective term is governed principally by the earliest non-provisional priority claim, not by the 2018 issue date.
The relevant commercial planning point is that the patent’s ordinary expiration is expected in the late 2020s, generally around the 2027-2028 period depending on the recorded patent-term calculation. The precise endpoint should be taken from the current USPTO Patent Center record and the FDA Orange Book entry because patent-term adjustment, terminal disclaimers and regulatory extensions can alter the operative date. [1,2]
The patent is therefore not an indefinite barrier. Its value is concentrated in the period before the applicable late-2020s expiration date and in its ability to complicate abbreviated new drug application litigation.
Patent term versus FDA exclusivity
Patent expiration and FDA exclusivity are separate rights.
- New chemical entity exclusivity for linagliptin is not the principal remaining barrier for Jentadueto.
- Combination-product exclusivity, if any, does not replace listed patent protection.
- A generic applicant may challenge listed patents through Paragraph IV certification before all listed patents expire.
- FDA approval may be delayed by statutory patent-restraint provisions even when other patents remain valid but are not listed for the particular product.
What is the Orange Book status of US Patent 10,022,379?
The patent has been associated with Jentadueto regulatory protection in FDA patent listings. Orange Book status must be evaluated at the product level because the listing may differ between:
- Jentadueto immediate-release tablets;
- Jentadueto XR extended-release tablets;
- 2.5 mg/500 mg products;
- 2.5 mg/850 mg products;
- 2.5 mg/1,000 mg products; and
- 5 mg/500 mg or 5 mg/1,000 mg products.
A listing does not establish validity or infringement. It provides notice of the sponsor’s asserted patent rights and triggers the Hatch-Waxman framework when an ANDA applicant files a Paragraph IV certification.
The patent’s formulation limitations are important in Orange Book litigation. An ANDA applicant can attempt to avoid infringement by using:
- a different stabilizer;
- a different stabilizer concentration;
- a different tablet architecture;
- a different linagliptin-to-arginine ratio;
- a formulation outside the claimed percentage ranges; or
- a dosage form not covered by the listed claims.
What Paragraph IV challenges and litigation affect this patent?
A Paragraph IV challenge would likely focus on claim construction, written description, enablement, obviousness and infringement. The most consequential issues are formulation-specific.
Likely infringement disputes
A generic applicant would examine whether its proposed product contains:
- L-arginine, L-lysine or L-histidine;
- the claimed amount of the stabilizer;
- linagliptin within the claimed percentage range;
- metformin within the claimed percentage range;
- a mono-layer tablet;
- a film coat; and
- the claimed linagliptin-to-arginine ratio.
The “amount sufficient to suppress degradation” language may generate disputes over whether the limitation is structural, functional or both. The percentage ranges provide additional objective limitations, but overlapping commercial formulations may still create infringement exposure under the doctrine of equivalents.
Likely validity disputes
An ANDA challenger could argue that the claimed combination was obvious in view of:
- known linagliptin tablets;
- known metformin formulations;
- conventional alkaline stabilizers;
- routine excipient screening; and
- prior-art combination therapy for type 2 diabetes.
Boehringer’s counterargument would rely on the specific stability problem, the selected basic amino acid, the claimed concentration window and the ability to produce a stable low-dose linagliptin tablet with a high metformin load.
No conclusion on validity follows from the patent’s issuance or Orange Book listing. A court or the Patent Trial and Appeal Board would evaluate the claims against the full prior-art record.
How strong is the patent estate for Jentadueto?
The estate is stronger against a formulation that closely copies the marketed tablet than against a technically differentiated formulation.
| Risk factor |
Assessment |
| Core linagliptin composition |
Depends on separate linagliptin compound patents |
| Linagliptin-metformin combination |
High relevance to Jentadueto products |
| L-arginine stabilization |
Central limitation of claims 8, 12 and 16 |
| 2.5 mg/500 mg product |
High claim overlap risk |
| 2.5 mg/850 mg product |
High claim overlap risk |
| 2.5 mg/1,000 mg product |
High claim overlap risk |
| 5 mg products |
Covered by claims 1 and 3, but not all narrower claims |
| XR products |
Must be analyzed separately against release-profile and formulation claims |
| Non-arginine formulation |
May avoid claims limited to L-arginine but not necessarily claims covering the broader amino-acid class |
| Non-tablet product |
May avoid the asserted tablet claims |
The patent is strongest where the proposed generic uses a conventional Jentadueto-like tablet with the same stabilizer and comparable composition percentages. It is weaker where the applicant has designed around the stabilizer, tablet layer, dosage strength or mass-percentage requirements.
What generic entry risks exist for linagliptin-metformin products?
A generic entrant faces several possible launch scenarios.
Scenario 1: Paragraph III certification
The applicant accepts the listed patent and waits for expiration. This is the lowest litigation-risk path but delays market entry until the applicable patent barrier ends.
Scenario 2: Paragraph IV certification
The applicant alleges that the patent is invalid, unenforceable or not infringed. The sponsor may file an infringement action within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman Act. [5]
Scenario 3: Formulation design-around
The applicant develops a tablet outside the claims. Potential design-around strategies include replacing L-arginine, changing the tablet core structure, adjusting the stabilizer ratio or selecting a formulation outside the percentage ranges. A design-around must still satisfy stability, dissolution, bioequivalence and manufacturing requirements.
Scenario 4: At-risk launch
A generic may launch before final resolution if the stay has expired or if litigation does not result in an injunction. This creates potential damages exposure and possible market disruption.
For business planning, the most material risk is not whether a generic contains linagliptin and metformin. It is whether the product reproduces the patented stability solution and tablet composition.
How does US Patent 10,022,379 compare with linagliptin compound patents?
The patent has a narrower scope than a compound patent.
| Issue |
Compound patent |
US 10,022,379 |
| Protected subject |
Linagliptin molecule |
Defined linagliptin-metformin tablet and use |
| Formulation dependence |
No |
Yes |
| Metformin required |
No |
Yes |
| Basic amino acid required |
No |
Yes |
| Tablet structure required |
Usually no |
Yes |
| Design-around potential |
Low before compound expiry |
Higher |
| Relevance to other linagliptin products |
Broad |
Limited |
| Relevance to Jentadueto |
Indirect or direct depending on patent |
Direct |
A generic that avoids this patent may still face separate linagliptin compound, formulation or method-of-use patents. Conversely, expiration or invalidation of this patent would not necessarily eliminate all barriers to a Jentadueto generic.
What manufacturing and intellectual-property barriers remain?
The principal manufacturing barrier is reproducible stabilization of a very low-dose DPP-4 inhibitor in a tablet containing a high proportion of metformin hydrochloride. The patent’s claimed L-arginine solution addresses degradation control in the finished dosage form.
A competing manufacturer must demonstrate:
- chemical stability through shelf life;
- acceptable dissolution;
- content uniformity for low-dose linagliptin;
- compatibility with metformin and excipients;
- bioequivalence to the reference product;
- commercial-scale blending and compression performance; and
- regulatory compliance for the selected dosage form.
A design-around can reduce patent risk but increase technical and regulatory risk. The commercial value of the patent therefore extends beyond its literal claim scope.
What is the commercial exposure associated with the patent?
Jentadueto is a combination product in the DPP-4 inhibitor and biguanide markets. Its revenue exposure depends on:
- U.S. prescription volume;
- net pricing;
- payer substitution;
- availability of separate-component therapy;
- competition from other DPP-4/metformin combinations;
- competition from GLP-1 receptor agonists and SGLT2 inhibitors; and
- the timing of generic or authorized-generic entry.
The patent is most valuable for preserving branded combination-tablet pricing. A generic entrant could face substitution pressure even if patients remain on linagliptin plus metformin as separate tablets. The combination product’s commercial advantage is dosing convenience, which can be weakened by generic availability of the components.
Key Takeaways
- US Patent 10,022,379 is directed to linagliptin-metformin tablets containing a basic amino-acid stabilizer.
- The most important stabilizer is L-arginine, although broader claims identify L-lysine and L-histidine.
- Claims 9-11 and 17-19 are closely aligned with 2.5 mg linagliptin combined with 500 mg, 850 mg or 1,000 mg metformin.
- Claim 12 adds a mono-layer tablet, L-arginine, fillers, binders and a defined linagliptin-to-arginine ratio.
- The patent is narrower than linagliptin compound patents and can potentially be designed around.
- Generic risk is highest for a Jentadueto-like formulation using L-arginine and comparable tablet percentages.
- The operative patent endpoint is in the late 2020s, subject to the recorded patent-term calculation.
- Orange Book listing creates Hatch-Waxman litigation risk but does not establish patent validity.
- A Paragraph IV challenge would likely focus on obviousness, stability evidence, claim construction and formulation design-around issues.
FAQs
Does US Patent 10,022,379 cover linagliptin alone?
No. The asserted claims require linagliptin in combination with metformin hydrochloride and a basic amino-acid stabilizer in a specified tablet formulation.
Does the patent cover Jentadueto XR?
Not automatically. Jentadueto XR must be analyzed against the claims of this patent and any separate extended-release formulation patents. The claimed mono-layer and film-coated tablet limitations may not map to every extended-release architecture.
Can a generic use L-arginine and avoid the patent?
Possibly, but only if the entire formulation falls outside the claimed amounts, ratios, tablet structure or other limitations. Changing a single excipient parameter does not guarantee non-infringement.
Is claim 20 broader than claim 1 because it recites glycemic control?
Not materially for formulation purposes. Claim 20 retains the key ingredient, dosage, tablet, stabilizer and percentage limitations. Its principal difference is the therapeutic-use wording.
Does patent expiration guarantee immediate generic launch?
No. FDA approval, regulatory exclusivity, other listed patents, separate linagliptin patents and litigation outcomes can affect launch timing.
References
- United States Patent and Trademark Office. (2018). U.S. Patent No. 10,022,379, Pharmaceutical composition comprising linagliptin and metformin.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Jentadueto and Jentadueto XR approval records.
- Boehringer Ingelheim International GmbH. (2018). U.S. Patent No. 10,022,379 prosecution and patent record. United States Patent and Trademark Office Patent Center.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments.
